Advertisement
Canada markets open in 42 minutes
  • S&P/TSX

    21,953.80
    +78.01 (+0.36%)
     
  • S&P 500

    5,509.01
    +33.92 (+0.62%)
     
  • DOW

    39,331.85
    +162.33 (+0.41%)
     
  • CAD/USD

    0.7325
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    82.90
    +0.09 (+0.11%)
     
  • Bitcoin CAD

    81,966.20
    -3,852.48 (-4.49%)
     
  • CMC Crypto 200

    1,293.45
    -41.47 (-3.10%)
     
  • GOLD FUTURES

    2,365.00
    +31.60 (+1.35%)
     
  • RUSSELL 2000

    2,033.87
    +3.81 (+0.19%)
     
  • 10-Yr Bond

    4.4140
    -0.0220 (-0.50%)
     
  • NASDAQ futures

    20,212.50
    -42.75 (-0.21%)
     
  • VOLATILITY

    12.13
    +0.10 (+0.83%)
     
  • FTSE

    8,156.42
    +35.22 (+0.43%)
     
  • NIKKEI 225

    40,580.76
    +506.07 (+1.26%)
     
  • CAD/EUR

    0.6793
    -0.0007 (-0.10%)
     

Some Angi Inc. (NASDAQ:ANGI) Analysts Just Made A Major Cut To Next Year's Estimates

One thing we could say about the analysts on Angi Inc. (NASDAQ:ANGI) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.

Following the latest downgrade, the ten analysts covering Angi provided consensus estimates of US$1.7b revenue in 2023, which would reflect an uncomfortable 12% decline on its sales over the past 12 months. Losses are predicted to fall substantially, shrinking 46% to US$0.14. Yet before this consensus update, the analysts had been forecasting revenues of US$2.1b and losses of US$0.11 per share in 2023. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.

Check out our latest analysis for Angi

earnings-and-revenue-growth
earnings-and-revenue-growth

The consensus price target fell 5.6% to US$4.88, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Angi analyst has a price target of US$9.00 per share, while the most pessimistic values it at US$2.75. We would probably assign less value to the forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be possible to derive much meaning from the consensus price target, which is after all just an average of this wide range of estimates.

ADVERTISEMENT

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 12% annualised revenue decline to the end of 2023. That is a notable change from historical growth of 15% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 9.1% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Angi is expected to lag the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Angi. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Angi's revenues are expected to grow slower than the wider market. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of Angi.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Angi analysts - going out to 2025, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here